Kelso Pharma builds for future growth with appointment of life sciences leader as Chief Operating Officer
Kelso Pharma builds for future growth with appointment of life sciences leader as Chief Operating Officer
Kelso Pharma, the growing UK-based specialty pharmaceuticals business, has appointed life sciences leader, Dr. Bee Koen Low, as its first Chief Operating Officer.
With over 20 years’ experience in the pharmaceutical industry, Bee brings extensive scientific expertise and understanding of the sector to the role, including in the key areas of: M&A due diligence and integrations, technology transfers; supply chain strategy; and pipeline development, as Kelso Pharma gears up for further growth in what has already been a busy 2025 for the business. Bee has spent over 10 years at ADVANZ PHARMA in a number of leadership positions, focusing on project management, technical operations and operations diligence and integration. She was heavily involved in merger and acquisition, working with business partners across the globe. Prior to that, Bee was at GW Pharmaceuticals (now part of Jazz Pharmaceuticals), where she was instrumental in advancing product pipeline development, resulting in novel products that are now successfully marketed in the UK and US.
Kelso Pharma is focused on bringing innovative, value-added, specialty medicines to international healthcare markets, providing products that improve the lives of patients in a cost-effective and ethical manner. The company is growing through a blend of company and product acquisitions, partnerships and organic growth internationally.
Bee’s appointment follows several important announcements from the business in 2025 so far, including the acquisition of UK pharma business, ALTURiX, the appointment of Giovanni Mauri as General Manager of Velit Biopharma in Italy and securing £140m of acquisition funding to accelerate its growth plans, with the appointment of former ADVANZ PHARMA CEO, Graeme Duncan, as Non-Executive Director, strengthening the leadership team.
Commenting on the appointment, Kelso Pharma CEO, Dr. Tom Stratford, said:
“As Kelso Pharma continues to grow in the UK and across Europe, it’s vital we build a leadership team that can take us to the next level. Bee joining us as Chief Operating Officer is a statement of intent of our ambition and determination to organically grow the business to support as many patients as possible.
“I’m looking forward to working with Bee as we build a truly pan European pharma business.”
Dr. Bee Koen Low, added:
“It’s an incredibly exciting time to be joining the Kelso Pharma team. The growth the business has experienced in the past few years has been fantastic and I’m looking forward to playing a key role in supporting our team continue to grow the business across Europe, as we aim to support as many patients as we can.”
Ends
Further enquiries:
Callum Spreng Tel: 07803 970103
Spreng Thomson callum@sprengthomson.com
Dylan Macdonald Tel: 07740 546 030
Spreng Thomson dylan@sprengthomson.com
Kelso Pharma
Kelso Pharma is committed to bringing innovative, value added, specialty medicines to the European healthcare markets that provide meaningful benefits to patients and create added value for healthcare stakeholders.
The company is backed by Apposite Capital LLP, a private equity firm specialising in investing in SME businesses in healthcare. The Kelso pharma team has extensive experience in growing and running a specialty pharma business across Europe.
Stirling Anglian Pharmaceuticals
Based in the UK, Stirling Anglian is committed to medicines optimisation. It has sourced and developed a portfolio of medicines to help the NHS curb waste – across a range of conditions that currently place unnecessary and avoidable pressure on NHS resources. At a time when there is such pressure on the NHS to reduce costs the company believes it provides a real and practical solution.
It works closely with stakeholders across the NHS to identify real-world problems and develop value-based solutions that support the delivery of efficient and cost-effective healthcare.
www.stirlinganglianpharmaceuticals.com
Velit Biopharma
Velit Biopharma specialises in developing and registering “hard to make” medicines which it then makes available to patients through partnerships with pharma companies and distributors across Europe, Asia and the Middle East. It has more than 100 partnerships in 48 regions/countries covering 167 products, with more than 15 further launches with existing partners planned for 2024 onwards. Velit’s therapeutic focus on gastroenterology, dermatology and women’s health, complements Kelso’s existing portfolio of medicines.
ALTURiX
ALTURiX is a dynamic pharmaceutical company that is committed to building and nurturing meaningful partnerships with its customers in the UK, and internationally. Acquired by Kelso Pharma in February 2025, ALTURiX has seven branded medicines in the UK market today, driving double digit topline revenue growth. These are in the therapeutic areas of central nervous system, respiratory disease and endocrinology. It has two further products in development.
Apposite Capital LLP
Apposite Capital solely focuses on healthcare. It works closely with management teams, providing operational support and strategic guidance as much as capital to together build market-leading companies.
Apposite invests in high potential commercial stage companies across Europe, tailoring its investment to each company’s needs and considering all types of financing structures (minority, growth, buy-out, buy-in, etc).
Apposite has an in-depth sector knowledge, covering key aspects of the healthcare industry
internationally, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies both organically and inorganically.
Apposite Capital was established in 2006 and is headquartered in London, UK.
Editor Details
-
Company:
- PHARMIWEB 2002 LIMITED
-
Name:
- Simon Brough
- Email:
